Drug Sellers Move To Finalize $250M TriCor Settlement

Law360, New York (April 13, 2009, 12:00 AM EDT) -- A group of drug vendors has moved to finalize a $250 million class action settlement with Abbott Laboratories, which would put to rest a long-running antitrust suit accusing the drug company of blocking generic versions of the cholesterol drug TriCor from the market.

The motion for final settlement, filed Thursday in the U.S. District Court for the District of Delaware, resolves the drug vendors' claims that Abbott and its French partner Fournier Industrie et Santé conspired to block generic pharmaceutical companies from breaking into the lucrative...
To view the full article, register now.